Lysogene S.A.

BATS-CHIXE:LYSP Stock Report

Market Cap: €11.4m

Lysogene Valuation

Is LYSP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LYSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LYSP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYSP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LYSP?

Key metric: As LYSP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LYSP. This is calculated by dividing LYSP's market cap by their current revenue.
What is LYSP's PS Ratio?
PS Ratio1.6x
Sales€6.95m
Market Cap€11.40m

Price to Sales Ratio vs Peers

How does LYSP's PS Ratio compare to its peers?

The above table shows the PS ratio for LYSP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
VRCI Verici Dx
2.1x78.8%UK£7.0m
PBX ProBiotix Health
5xn/aUK£10.7m
GENF Genflow Biosciences
10.5xn/aUK£6.3m
APTA Aptamer Group
6.5xn/aUK£5.3m
LYSP Lysogene
1.6xn/a€11.4m

Price-To-Sales vs Peers: LYSP is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (113.8x).

Price to Sales Ratio vs Industry

How does LYSP's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.n/a19.9%
LYSP Lysogene
 1.6xn/aUS$11.89m
GNS Genus
1.7x3.5%US$1.50b
OXB Oxford Biomedica
4.4x21.0%US$551.49m
No. of Companies8PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a37.2%
LYSP Lysogene
 1.6xn/aUS$11.89m
No more companies

Price-To-Sales vs Industry: LYSP is good value based on its Price-To-Sales Ratio (1.6x) compared to the UK Biotechs industry average (17.2x).

Price to Sales Ratio vs Fair Ratio

What is LYSP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LYSP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LYSP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€65.15

7D

-1.8%

1Y

30.4%

Formycon

€826.3m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€46.95

7D

-2.9%

1Y

-26.3%

Regeneron Pharmaceuticals

US$84.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$797.20

7D

-3.5%

1Y

-1.1%